Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.31
NAS:OPK's Cash-to-Debt is ranked lower than
58% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. NAS:OPK: 1.31 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:OPK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 13.08 Max: No Debt
Current: 1.31
Equity-to-Asset 0.75
NAS:OPK's Equity-to-Asset is ranked higher than
74% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NAS:OPK: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:OPK' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.67 Max: 0.96
Current: 0.75
-0.41
0.96
Piotroski F-Score: 4
Altman Z-Score: 4.19
Beneish M-Score: 0.53
WACC vs ROIC
20.02%
-0.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -2.52
NAS:OPK's Operating Margin % is ranked lower than
78% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. NAS:OPK: -2.52 )
Ranked among companies with meaningful Operating Margin % only.
NAS:OPK' s Operating Margin % Range Over the Past 10 Years
Min: -31624.44  Med: -82.88 Max: -2.52
Current: -2.52
-31624.44
-2.52
Net Margin % -0.80
NAS:OPK's Net Margin % is ranked lower than
75% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NAS:OPK: -0.80 )
Ranked among companies with meaningful Net Margin % only.
NAS:OPK' s Net Margin % Range Over the Past 10 Years
Min: -31688.9  Med: -118.52 Max: -0.8
Current: -0.8
-31688.9
-0.8
ROE % -0.49
NAS:OPK's ROE % is ranked lower than
73% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.12 vs. NAS:OPK: -0.49 )
Ranked among companies with meaningful ROE % only.
NAS:OPK' s ROE % Range Over the Past 10 Years
Min: -3196.93  Med: -21.01 Max: -0.49
Current: -0.49
-3196.93
-0.49
ROA % -0.35
NAS:OPK's ROA % is ranked lower than
72% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. NAS:OPK: -0.35 )
Ranked among companies with meaningful ROA % only.
NAS:OPK' s ROA % Range Over the Past 10 Years
Min: -1352.71  Med: -13.92 Max: -0.35
Current: -0.35
-1352.71
-0.35
ROC (Joel Greenblatt) % -25.73
NAS:OPK's ROC (Joel Greenblatt) % is ranked lower than
80% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. NAS:OPK: -25.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:OPK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -130662.93  Med: -367.75 Max: -25.73
Current: -25.73
-130662.93
-25.73
3-Year Revenue Growth Rate 85.10
NAS:OPK's 3-Year Revenue Growth Rate is ranked higher than
97% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. NAS:OPK: 85.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:OPK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -11.6 Max: 152
Current: 85.1
0
152
3-Year EBITDA Growth Rate 27.70
NAS:OPK's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. NAS:OPK: 27.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:OPK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -74.6  Med: 6.6 Max: 161.2
Current: 27.7
-74.6
161.2
3-Year EPS without NRI Growth Rate -16.40
NAS:OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. NAS:OPK: -16.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:OPK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.4  Med: -1.6 Max: 152.4
Current: -16.4
-69.4
152.4
GuruFocus has detected 3 Warning Signs with OPKO Health Inc $NAS:OPK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:OPK's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OPK Guru Trades in Q1 2016

Ken Fisher 37,867 sh (+0.11%)
Paul Tudor Jones Sold Out
George Soros Sold Out
Murray Stahl 67,206 sh (-15.60%)
Mario Gabelli 100,775 sh (-30.39%)
Joel Greenblatt 30,179 sh (-74.93%)
» More
Q2 2016

OPK Guru Trades in Q2 2016

Paul Tudor Jones 27,173 sh (New)
Joel Greenblatt 267,485 sh (+786.33%)
Ken Fisher 37,826 sh (-0.11%)
Murray Stahl 66,333 sh (-1.30%)
Mario Gabelli 97,050 sh (-3.70%)
» More
Q3 2016

OPK Guru Trades in Q3 2016

Jim Simons 1,412,757 sh (New)
George Soros 59,837 sh (New)
John Burbank 12,234 sh (New)
Joel Greenblatt 535,214 sh (+100.09%)
Paul Tudor Jones 36,248 sh (+33.40%)
Ken Fisher 38,229 sh (+1.07%)
Mario Gabelli 97,050 sh (unchged)
Murray Stahl 60,179 sh (-9.28%)
» More
Q4 2016

OPK Guru Trades in Q4 2016

Ken Fisher 39,229 sh (+2.62%)
John Burbank Sold Out
Jim Simons Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 94,550 sh (-2.58%)
Murray Stahl 58,149 sh (-3.37%)
Joel Greenblatt 167,109 sh (-68.78%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:PTHN, NYSE:TARO, OTCPK:STDAF, NYSE:VRX, OTCPK:HYPMY, NAS:NBIX, NAS:MDCO, OTCPK:HKMPF, NAS:ENDP, NAS:HZNP, NAS:AKRX, NAS:IRWD, NYSE:RDY, OTCPK:IPSEY, NAS:RDUS, NAS:PCRX, NAS:SUPN, OTCPK:HLUYY, NAS:EGRX, NAS:MNTA » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.

OPKO Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.

Top Ranked Articles about OPKO Health Inc

Weekly CEO Buys Highlights The largest insider buys of Macquarie, OPKO, New Residential Investment, Lannett and DeVry
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlights Insiders purchase shares of Macquarie, OPKO, First Bancorp
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlights Spotlight shines on OPKO and Guess?
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Top Insider Buys Highlight for Week of Jan. 6 Insiders bought shares at Opko Health and Resolute Energy
The largest insider buys this week were for OPKO Health Inc. (NASDAQ:OPK), Compass Diversified Holdings (NYSE:CODI), Acceleron Pharma Inc. (NASDAQ:XLRN) and Resolute Energy Corp. (NYSE:REN). Read more...
Weekly CEO Buys Highlight Insiders invest in Natus, OPKO, Mobile Mini, S&T Bancorp, Investors Real Estate
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
CEO Phillip Frost Buys OPKO Health Insider purchased 24,800 shares
Phillip Frost (Insider Trades), CEO, chairman and 10% owner of OPKO Health Inc. (NASDAQ:OPK), purchased 24,800 shares of the company on Oct. 10. The average price per share was $9.82, for a total transaction of $243,536. Read more...
Weekly CEO Buys: Abbott Laboratories, GE, OPKO Health Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys: Ryman Hospitality, OPKO Health, Actuant Corp. Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight Stock purchases from QEP Resources, OPKO Health and Korn/Ferry International CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Insider Buys of More Than $100,000: Opko Health Chairman purchases 16,000 shares in company
Opko Health Inc. (NASDAQ:OPK) CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 16,000 shares on June 14 at a price of $9.01 per share. The total transaction amount was $144,160. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.26
OPK's PB Ratio is ranked higher than
60% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. OPK: 2.26 )
Ranked among companies with meaningful PB Ratio only.
OPK' s PB Ratio Range Over the Past 10 Years
Min: 2.17  Med: 8.67 Max: 800
Current: 2.26
2.17
800
PS Ratio 3.75
OPK's PS Ratio is ranked lower than
60% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. OPK: 3.75 )
Ranked among companies with meaningful PS Ratio only.
OPK' s PS Ratio Range Over the Past 10 Years
Min: 3.61  Med: 31.97 Max: 158.13
Current: 3.75
3.61
158.13
EV-to-EBITDA 98.40
OPK's EV-to-EBITDA is ranked lower than
95% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. OPK: 98.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -34.6 Max: 539.9
Current: 98.4
-146.6
539.9
Current Ratio 1.97
OPK's Current Ratio is ranked lower than
56% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. OPK: 1.97 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.1 Max: 415
Current: 1.97
0.88
415
Quick Ratio 1.80
OPK's Quick Ratio is ranked higher than
53% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. OPK: 1.80 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.68 Max: 415
Current: 1.8
0.48
415
Days Inventory 25.28
OPK's Days Inventory is ranked higher than
93% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. OPK: 25.28 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 25.28  Med: 233.05 Max: 500.07
Current: 25.28
25.28
500.07
Days Sales Outstanding 66.84
OPK's Days Sales Outstanding is ranked higher than
60% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. OPK: 66.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 163.64 Max: 727.85
Current: 66.84
38.86
727.85
Days Payable 35.89
OPK's Days Payable is ranked lower than
82% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. OPK: 35.89 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 35.89  Med: 112.55 Max: 1499.3
Current: 35.89
35.89
1499.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.30
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. OPK: -21.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -14.4 Max: 0.4
Current: -21.3
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.14
OPK's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
57% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. OPK: 3.14 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OPK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.04  Med: 9.57 Max: 177.5
Current: 3.14
3.04
177.5
Price-to-Median-PS-Value 0.12
OPK's Price-to-Median-PS-Value is ranked higher than
98% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. OPK: 0.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.29 Max: 30
Current: 0.12
0.11
30
Earnings Yield (Greenblatt) % -0.98
OPK's Earnings Yield (Greenblatt) % is ranked lower than
78% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. OPK: -0.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1  Med: 0.5 Max: 0.5
Current: -0.98
-1
0.5

More Statistics

Revenue (TTM) (Mil) $1,222
EPS (TTM) $ -0.02
Beta2.42
Short Percentage of Float24.46%
52-Week Range $7.99 - 12.15
Shares Outstanding (Mil)557.53

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,250 1,365 1,607 2,151
EPS ($) -0.08 -0.01 0.26 0.70
EPS without NRI ($) -0.08 -0.01 0.26 0.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Feb 13 2017 
Weekly CEO Buys Highlights Feb 06 2017 
OPKO CEO Invests in Company Jan 30 2017 
Weekly CEO Buys Highlight Jan 22 2017 
Weekly CEO Buys Highlights Jan 09 2017 
Top Insider Buys Highlight for Week of Jan. 6 Jan 07 2017 
Weekly CEO Buys Highlights Dec 06 2016 
Weekly CEO Buys Highlight Oct 31 2016 
Weekly CEO Buys Highlights Oct 24 2016 
Weekly CEO Buys Highlight Oct 17 2016 

More From Other Websites
OPKO Health to Participate at Upcoming Healthcare Investment Conferences Feb 21 2017
Biotech Industry Positioned for a Potential Breakout in 2017: Today's Reports on Array Biopharma and... Feb 17 2017
OPKO HEALTH, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2017
OPKO Spain to Start Trial of Once-A-Year Intra-Articular Injectable for Osteoarthritis Feb 08 2017
OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer Feb 07 2017
Opko Health subsidiary dives into human genome research Feb 02 2017
OPKO’S GeneDx Announces Research Collaboration with the Wellcome Trust Sanger Institute Feb 01 2017
OPKO Health CEO on Trump Administration, Biotech Outlook Jan 31 2017
OPKO Health CEO Frost on 4Kscore Test for Prostate Cancer Jan 30 2017
Billionaire's $100M gift to SoFla university funneled to STEM efforts Jan 27 2017
OPKO HEALTH, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 24 2017
Opko Health Eyes Better 2017 After Disastrous 2016 Jan 16 2017
OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 10 2017
Opko Health investee company launches into new partnership Jan 10 2017
OPKO Investee Zebra Biologics Announces Collaboration with AbbVie to Discover New Antibody... Jan 10 2017
OPKO Announces Initiation of Claros® 1 Clinical Trial for Total PSA Jan 09 2017
Weekly CEO Buys Highlights Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)